Compare GFF & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | BLLN |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | 1994 | 2025 |
| Metric | GFF | BLLN |
|---|---|---|
| Price | $102.08 | $88.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $105.00 | ★ $126.71 |
| AVG Volume (30 Days) | 321.2K | ★ 779.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | ★ 2.97 | 0.48 |
| Revenue | ★ $2,519,926,000.00 | $305,112,000.00 |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | ★ $34.40 | $195.65 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $65.01 | $61.96 |
| 52 Week High | $108.57 | $150.44 |
| Indicator | GFF | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 33.40 |
| Support Level | $86.68 | $83.59 |
| Resistance Level | $108.57 | $99.29 |
| Average True Range (ATR) | 3.59 | 6.68 |
| MACD | 0.40 | -4.24 |
| Stochastic Oscillator | 69.67 | 1.13 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.